Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cytek Biosciences (CTKB) EPS (Weighted Average and Diluted) (2020 - 2026)

Cytek Biosciences filings provide 5 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.34 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 585.71% to -$0.34 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.51, a 920.0% decrease, with the full-year FY2025 number at -$0.52, down 940.0% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.34 in Q4 2025 for Cytek Biosciences, down from -$0.04 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.07 in Q4 2024 to a low of -$0.34 in Q4 2025.
  • Median EPS (Weighted Average and Diluted) over the past 4 years was -$0.04 (2025), compared with a mean of -$0.04.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 600.0% in 2023 and later soared 120.0% in 2024.
  • Cytek Biosciences' EPS (Weighted Average and Diluted) stood at $0.03 in 2022, then soared by 33.33% to $0.04 in 2023, then surged by 75.0% to $0.07 in 2024, then crashed by 585.71% to -$0.34 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.34 (Q4 2025), -$0.04 (Q3 2025), and -$0.04 (Q2 2025) per Business Quant data.